GPC2 and neuroblastoma: The research indicated that among three GPC2-CAR constructs, anti-GPC2 CT3 with a CD28 hinge, CD28 transmembrane, and 4-1BB co-stimulatory domain demonstrated the most effective pre-clinical activity against NB.